<!DOCTYPE HTML>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
    <title>Xingyu Chen – Cancer Genomics @ JHU</title>

    <!-- ===================== GLOBAL STYLES ===================== -->
    <style>
      /*─ 1. Typography & variables ─*/
      @font-face {
        font-family: "Inter";
        font-weight: 400 700;
        src: url("https://fonts.gstatic.com/s/inter/v12/UcCO3FwrK_x90DW4ZGdE.woff2") format("woff2-variations");
        font-display: swap;
      }
      :root {
        --accent: #0052cc;
        --bg-light: #fafbfd;
        --bg-alt:  #f3f6fa;
      }
      html { font-size: 16px; }
      body {
        margin: 0;
        font-family: "Inter", system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial, sans-serif;
        line-height: 1.6;
        color: #333;
        background: var(--bg-light);
      }
      h1,h2,h3,h4,h5,h6{font-weight:600;color:#111;line-height:1.25;margin:0 0 .6em}
      h1{font-size:1.9rem} h2{font-size:1.6rem} h3{font-size:1.3rem} h4{font-size:1.15rem} h5{font-size:1rem}
      p{margin:0 0 1.2em} ul{margin:0 0 1.2em 1.5em;padding:0}
      a{color:var(--accent);text-decoration:none}
      a:hover,a:focus{text-decoration:underline}

      /*─ 2. helpers ─*/
      .container{width:min(92%,1080px);margin-inline:auto}
      .left{text-align:left}
      .image.fit img{width:100%;height:auto;border-radius:8px}
      .badge-container{display:inline-flex;align-items:center;gap:6px;margin-left:6px}

      /*─ 3. header / nav ─*/
      #header{
        position:relative;
        background:transparent!important;
        padding:2.5rem 0 2rem;
        text-align:center;
      }
      #header::before{
        content:"";
        position:absolute;
        inset:0;
        background:url("images/WechatIMG240.jpg") center/cover no-repeat;
        opacity:0.95;
        z-index:-1;
        pointer-events:none;
      }

      #header header{display:flex;flex-direction:column;align-items:center;gap:.8rem}
      #header .image.avatar img{width:140px;height:140px;border-radius:50%;object-fit:cover}
      #nav ul{display:flex;gap:1.2rem;flex-direction:column;list-style:none;margin:1.5rem 0;padding:0;justify-content:center}
      #nav a{font-weight:600;position:relative;padding:.3rem .1rem}
      #nav a.active::after{content:"";position:absolute;left:0;bottom:-4px;width:100%;height:2px;background:var(--accent)}
      #header footer .icons{display:flex;justify-content:center;gap:1rem;list-style:none;padding:0}
      .orcid-icon{width:24px;height:24px;vertical-align:middle}

      /*─ 4. sections ─*/
      section{padding:4rem 0}
      section:nth-of-type(even){background:var(--bg-alt)}
      .features article{margin-bottom:3rem}

      /*─ 5. experience lists ─*/
      .experience-title{margin:2rem 0 .6rem;font-weight:600}
      .experience-list{margin:0 0 1.2rem 1.5rem;list-style:disc outside}
      .experience-list li{margin-bottom:.4rem;padding-left:.25rem}
      .experience-list strong{color:var(--accent)}

      /*─ 6. footer ─*/
      #footer{background:#e8ecf2;padding:2rem 0;text-align:center}
      #footer ul{list-style:none;margin:0;padding:0;display:flex;justify-content:center;gap:1rem;flex-wrap:wrap}

      /*─ 7. responsive ─*/
      @media(max-width:650px){
        h1{font-size:1.6rem} h2{font-size:1.4rem}
      }
    </style>

    <!-- original theme css -->
    <link rel="stylesheet" href="assets/css/main.css" />
    <link rel="icon" href="images/web-icon_avatar.png" />
  </head>

  <body class="is-preload">
    <!-- ========== HEADER ========== -->
    <section id="header">
      <header>
        <span class="image avatar"><img src="images/avatar.png" alt="avatar" /></span>
        <h1 id="logo"><a href="#">Xingyu Chen</a></h1>
        <p>Baltimore, MD<br/>
           <a href="https://scholar.google.com/citations?user=Vj8vClIAAAAJ&hl=en&oi=ao" target="_blank">Google Scholar</a><br/>
           <a href="https://orcid.org/0000-0002-9284-4950" target="_blank">ORCID</a></p>
      </header>
      <nav id="nav">
        <ul>
          <li><a class="active" href="#about">About Me</a></li>
          <li><a href="#publications">Research Projects</a></li>
          <li><a href="#research">Research Experience</a></li>
          <li><a href="#cv">Academic CV</a></li>
          <li><a href="#contact">Contact</a></li>
        </ul>
      </nav>
      <footer>
        <ul class="icons">
          <li><a href="https://x.com/Xingyu_Chen_" class="icon brands fa-twitter" target="_blank"><span class="label">Twitter</span></a></li>
          <li><a id="mlink" href="#" class="icon solid fa-envelope"><span class="label">Email</span></a></li>
          <li><a href="https://orcid.org/0000-0002-9284-4950" target="_blank"><img src="images/orcid.png" alt="ORCID" class="orcid-icon"/></a></li>
        </ul>
      </footer>
    </section>

    <!-- ========== WRAPPER ========== -->
    <div id="wrapper">
      <div id="main">

        <!-- ABOUT -->
        <section id="about">
          <span class="image fit"><img src="images/Picture1.png" alt="Picture1" /></span>
          <div class="container">
            <header class="major"><h3>About Me</h3></header>
            <p>I am a first-year PhD student in Cell, Molecular, Development Biology, and Biophysics (CMDB) Program at Johns Hopkins University, specialising in urologic surgery and computational bioinformatics. My research integrates single-cell and spatial multi-omics with advanced machine-learning to dissect tumour heterogeneity and immune evasion in bladder and prostate cancers, uncovering actionable vulnerabilities for first-in-class precision therapies.</p>
            <p>Trained in China, I earned an <strong>MD-equivalent degree</strong> and an <strong>MSc in Oncology</strong> focused on urologic malignancies. I subsequently spent three years as a research bioinformatician in the Department of Urology at <strong>Cedars-Sinai Medical Center</strong>, where I conducted NIH-funded projects under my PI’s direction and mentored junior scientists, including a bioinformatician with a master’s degree from Columbia University and a visiting MD student from Tsinghua University.</p>
            <p>I have authored more than 20 peer-reviewed papers, including two in <strong><i>Nature</i></strong> —one as <strong>co-first author (2023)</strong> and one as <strong>sole first author (2025)</strong>. Our Y-chromosome study appeared on Nature’s cover and was highlighted by both the National Cancer Institute and the NIH. I also hold several U.S. patents, review manuscripts for more than 40 SCI-indexed journals, serve on multiple early-career editorial boards, and co-lead the “Tumorigenesis” WG sessions for the Prostate Cancer Foundation’s Young Investigator.</p>
            <p>My long-term ambition is to practise as a <strong>physician-scientist</strong> who harnesses computation, single-cell biology, and artificial intelligence to revolutionise cancer detection, prognostication, and treatment.</p>
            <h4>Research Interests</h4>
            <ul>
              <li>Cancer Immunotherapy & Tumor Microenvironment</li>
              <li>Bioinformatics and Computational Biology</li>
              <li>Multi-Omics Integration & Predictive Modeling & Radiogenomics</li>
              <li>Single-Cell & Spatial Transcriptomics</li>
              <li>Large Language Models in Genomics</li>
            </ul>
          </div>
        </section>

        <!-- RESEARCH PROJECTS -->
        <section id="publications">
          <div class="container">
            <header class="major"><h2>Research Projects</h2></header>

            <h4>(1) The Role of Y-Chromosome Loss in Immune Modulation and Tumorigenesis</h4>
            <img src="images/Selected Publications.png" class="img-fluid" alt="Selected Publications" />

            <div class="features">
              <!-- 2025 Nature paper -->
              <article>
                <div class="image-container">
                  <h5>Concurrent loss of the Y chromosome in cancer and T cells impacts outcome</h5>
                  <p><strong>Chen, X</strong>., Shen, Y., Choi, S. et al. Nature 642, 1041–1050 (2025). <strong>First author</strong>.
                    <a href="https://doi.org/10.1038/s41586-025-09071-2" target="_blank">https://doi.org/10.1038/s41586-025-09071-2</a>
                    <span class="badge-container">
                      <span class="__dimensions_badge_embed__" data-doi="10.1038/s41586-025-09071-2" data-style="small_circle"></span>
                      <span class="altmetric-embed" data-doi="10.1038/s41586-025-09071-2" data-badge-type="donut"></span>
                    </span>
                  </p>
                  <p class="left">In our 2025 Nature study (first authored by me), we demonstrated that age-related loss of the Y chromosome (LOY)—which affects up to 40% of elderly men—occurs not only in tumour cells but also spreads to infiltrating T cells; this “double-LOY” condition cripples anti-tumour immunity and predicts the worst survival across 4,000 male cancer samples and more than one million single-cell profiles. Mechanistically, losing key Y-linked genes (KDM5D, UTY, DDX3Y) weakens tumour antigen presentation, while LOY T cells become exhausted (↓ GZMB/PRF1, ↑ PD-1/CTLA-4), offering an explanation for men’s higher cancer burden. These findings argue for routine LOY testing in male-predominant cancers, careful exclusion of LOY T cells from cell therapies, and development of treatments that restore or block LOY-driven immune collapse.</p>
                  <p class="left"><i>Nature</i> <strong>News & Views (4 June 2025)</strong> spotlighted our Nature paper revealing Y-chromosome loss (LOY) in both tumour cells and infiltrating T cells. Commentators <strong>Nicholas McGranahan (University College London)</strong> and <strong>Rahul Roychoudhuri (University of Cambridge)</strong> contend that this coordinated LOY weakens antitumour immunity, enables escape, and predicts poorer survival. They urge clinicians to assess LOY in both compartments for prognosis, use Y-status to guide immuno- and cell-therapy choices, and investigate how Y-deficient tumours trigger LOY in nearby immune cells to discover new therapeutic targets.</p>
                  <img src="images/nature12.png" class="img-fluid" alt="nature12"/>
                  <h5> <strong>Nature Journal Headline</strong></h5>
                </div>
              </article>

              <!-- 2023 Nature paper -->
              <article>
                <div class="image-container">
                  <h5>Y chromosome loss in cancer drives growth by evasion of adaptive immunity</h5>
                  <p>Abdel-Hafiz, H.A., Schafer, J.M., <strong>Chen, X</strong>. et al. Nature 619, 624-631 (2023). <strong>Co-first author</strong>.
                    <a href="https://doi.org/10.1038/s41586-023-06234-x" target="_blank">https://doi.org/10.1038/s41586-023-06234-x</a>
                    <span class="badge-container">
                      <span class="__dimensions_badge_embed__" data-doi="10.1038/s41586-023-06234-x" data-style="small_circle"></span>
                      <span class="altmetric-embed" data-doi="10.1038/s41586-023-06234-x" data-badge-type="donut"></span>
                    </span>
                  </p>
                  <p class="left">Our 2023 Nature paper (co-first authored by me) delivered the first direct evidence that loss of the Y chromosome (LOY) in cancer cells reshapes anti-tumor immunity. Using mouse models and large human cohorts of bladder cancer, we showed that Y-negative tumors up-regulate PD-L1, drive T-cell exhaustion, and proliferate twice as fast as Y-positive tumors. Paradoxically, the same immune-evasive state renders LOY tumors markedly more responsive to immune-checkpoint blockade (e.g., atezolizumab). <strong>These findings uncover a causal link between sex-chromosome loss and immune escape, offer a mechanistic explanation for the higher incidence and poorer prognosis of many cancers in men, and position LOY as a predictive biomarker for immunotherapy benefit.</strong></p>
                </div>
              </article>
            </div>

            <h4>(2) Multi-Omics Biomarker Toolkit Driving Precision Oncology in Urologic Cancers</h4>
            <p class="left">My biomarker work spans several studies that converge on three advances: (1) <strong>AI-powered radiogenomics that pairs MRI with RNA-seq </strong> to stage muscle-invasive bladder cancer more accurately than imaging alone; (2) multi-omics immune signatures—covering <strong> pyroptosis, hypoxia, autophagy, ferroptosis, m6A and CD8-T-effector checkpoints</strong>—that stratify patients and predict checkpoint-inhibitor benefit across bladder, ovarian and other cancers; and (3) mechanistic discoveries (e.g., KDM5D/UTY loss, SRSF10-CDC25A splicing, lncRNA FOXD1-AS1) that reveal druggable pathways driving <strong>tumour metabolism and immune escape</strong>, together forming a toolkit for precision oncology.</p>

            <ol>
              <li>Qureshi TA*, <strong>Chen X*</strong>, Xie Y, Murakami K, Sakatani T, Kita Y, Kobayashi T, Miyake M, Knott SRV, Li D et al: MRI/RNA-Seq-Based Radiogenomics and Artificial Intelligence for More Accurate Staging of Muscle-Invasive Bladder Cancer. <em>Int J Mol Sci</em> 2023, 25(1). <strong>(Co-first author)</strong></li>
              <li><strong>Chen X</strong>, Xu R, He D, Zhang Y, Chen H, Zhu Y, Cheng Y, Liu R, Zhu R, Gong L et al: CD8(+) T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. <em>Oncogene</em> 2021, 40(43):6223-6234. <strong>(First author)</strong></li>
              <li><strong>Chen X*</strong>, Chen H*, Yao H, Zhao K, Zhang Y, He D, Zhu Y, Cheng Y, Liu R, Zhu R, Gong L et al: Turning up the heat on non-immunoreactive tumors: pyroptosis influences the tumor immune microenvironment in bladder cancer. <em>Oncogene</em> 2021, 40(45):6381-6393. <strong>(Co-first author)</strong></li>
              <li><strong>Chen X*</strong>, Lan H*, He D, Zhu Y, Xiao M, Lan H, Wang Z, Cao K: Analysis of Tumor Microenvironment Characteristics in Bladder Cancer: Implications for Immune Checkpoint Inhibitor Therapy. <em>Front Immunol</em> 2021, 12:672158. <strong>(Co-first author)</strong></li>
              <li><strong>Chen X*</strong>, Lan H*, He D, Xu R, Zhang Y, Cheng Y, Chen H, Xiao S, Cao K: Multi-Omics Profiling Identifies Risk Hypoxia-Related Signatures for Ovarian Cancer Prognosis. <em>Front Immunol</em> 2021, 12:645839. <strong>(Co-first author)</strong></li>
              <li><strong>Chen X*</strong>, Lan H*, He D, Wang Z, Xu R, Yuan J, Xiao M, Zhang Y, Gong L, Xiao S et al: Analysis of Autophagy-Related Signatures Identified Two Distinct Subtypes for Evaluating the Tumor Immune Microenvironment and Predicting Prognosis in Ovarian Cancer. <em>Front Oncol</em> 2021, 11:616133. <strong>(Co-first author)</strong></li>
              <li><strong>Chen X</strong>, Jin Y, Gong L, He D, Cheng Y, Xiao M, Zhu Y, Wang Z, Cao K: Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer. <em>Front Genet</em> 2020, 11:607. <strong>(First author)</strong></li>
              <li>Deng H, Tang F, Zhou M, Shan D, <strong>Chen X*</strong>, Cao K*: Identification and Validation of N6-Methyladenosine-Related Biomarkers for Bladder Cancer: Implications for Immunotherapy. <em>Front Oncol</em> 2022, 12:820242. <strong>(Co-corresponding author)</strong></li>
            </ol>
            <p>*These authors contributed equally</p>
          </div>
        </section>

        <!-- RESEARCH EXPERIENCE -->
        <section id="research">
          <div class="container">
            <header class="major"><h2>Research Experience</h2></header>

            <h4 class="experience-title">Research Rotations — Johns Hopkins University (2024)</h4>
            <ul class="experience-list">
              <li><strong>Clone-based WGS</strong> maps sub-clonal CNVs under <strong>Dr.&nbsp;Rajiv&nbsp;McCoy.</strong></li>
              <li><strong>DNA language models</strong> gain speed and accuracy with k-mer deduplication under <strong>Dr.&nbsp;Michael&nbsp;Schatz.</strong></li>
              <li><strong>Retinal organoid atlas</strong> integrates snRNA-seq to reveal developmental gaps under <strong>Dr.&nbsp;Bob&nbsp;Johnston.</strong></li>
              <li><strong>Seq-to-function PRS</strong> boosts gene-trait prediction via fine-tuned CNNs under <strong>Dr.&nbsp;Alexis&nbsp;Battle.</strong></li>
            </ul>

            <h4 class="experience-title">Research Bioinformatician I — Cedars-Sinai Medical Center (2022–2024)</h4>
            <ul class="experience-list">
              <li>Led four independent bioinformatics projects on tumor evolution, immunotherapy biomarkers, and spatial proteomics.</li>
              <li>Supervised two junior scientists, collaborated across six labs, and delivered analyses supporting NIH-funded grants.</li>
              <li>Published high-impact findings, including a <em>Nature</em> paper on Y-chromosome loss and immune evasion in bladder cancer.</li>
            </ul>

            <h4 class="experience-title">Research Associate I & Visiting Graduate Student — Cedars-Sinai Medical Center (2021–2022)</h4>
            <ul class="experience-list">
              <li>Integrated RNA-seq, ATAC-seq, and single-cell data to explore tumor microenvironment landscapes.</li>
              <li>Contributed to radiogenomics and multi-modal cancer staging using AI-enhanced MRI and RNA-seq datasets.</li>
              <li>Co-first author on three peer-reviewed publications during this period.</li>
            </ul>

            <h4 class="experience-title">Early Researcher — Third Xiangya Hospital, Central South University (2020–2021)</h4>
            <ul class="experience-list">
              <li>Conducted immunogenomic analyses on clinical samples from bladder and ovarian cancer patients.</li>
              <li>Initiated development of PyroScore and IMS scoring systems, which became key predictive models in later publications.</li>
            </ul>
          </div>
        </section>

        <!-- ACADEMIC CV -->
        <section id="cv">
          <div class="container">
            <header class="major"><h2>Academic CV</h2></header>

            <h4><strong>Previous Roles</strong></h4>
            <ul>
              <li><strong>Research Bioinformatician I</strong>, Cedars-Sinai Medical Center, 2022.08–2024.07</li>
              <li><strong>Research Associate I</strong>, Cedars-Sinai, 2022.04–2022.08</li>
              <li><strong>Visiting Graduate Student</strong>, Cedars-Sinai, 2021.09–2022.03</li>
            </ul>

            <h4>Skills</h4>
            <ul>
              <li><strong>Programming:</strong> R, Python, Linux</li>
              <li><strong>Omics:</strong> RNA-seq, ATAC-seq, scRNA-seq, DNA methylation, WGS/WES</li>
              <li><strong>AI/ML:</strong> WGCNA, LASSO, Deep Learning, Random Forest</li>
              <li><strong>Large language model in Genomics:</strong> Pretraining & fine-tuning LLMs · genomic transformer Enformer · Borzoi language model · Decima scheduling RL</li>
              <li><strong>Tools:</strong> CellRanger, Seurat, SCENIC, BioRender, Adobe Illustrator</li>
            </ul>

            <h4>Editorial & Peer Review Roles</h4>
            <ul>
              <li><strong>Youth Editor:</strong> <i>iMeta</i> (IF 33.2); <i>Asian Journal of Pharmaceutical Sciences</i> (IF 11.9); <i>Journal of Translational Internal Medicine</i> (IF 7.4) etc.</li>
              <li><strong>Review Editor:</strong> <i>Frontiers in Urology</i> (IF 1.1) etc.</li>
              <li><strong>Reviewer:</strong> <i>iMeta</i> (IF 33.2), <i>Oncogene</i> (IF 7.3), <i>Frontiers in Immunology</i> (IF 5.9), <i>Seminars in Cancer Biology</i> (IF 12.1) etc.</li>
            </ul>

            <h4>Invited Presentations</h4>
            <ul class="left">
              <li><strong>American Society of Clinical Oncology (ASCO) Annual Meeting 2023</strong>:
                <ul>
                  <li>X Chen, M Basu, S Knott, D Theodorescu. <i>CDH12 drives the development of the neuronal subtype in MIBC.</i> <i>Journal of Clinical Oncology</i> 41 (16_suppl), e16579-e16579, 2023 (Abstract)</li>
                  <li>X Chen, T Qureshi, Y Xie, S Knott, D Li, CJ Rosser, H Furuya. <i>Radiogenomics of muscle invasive bladder cancer.</i> <i>Journal of Clinical Oncology</i> 41 (16_suppl), e16587-e16587, 2023 (Abstract)</li>
                </ul>
              </li>
              <li><strong>American Urological Association (AUA) Annual Meeting 2023 – Chicago, IL</strong>:
                <ul>
                  <li><em>Oral Presentation, Breakthrough abstract (LBA03-09)</em>: X Chen (Speaker), M Basu, S Knott, D Theodorescu. <i>CDH12 Drives The Development Of The Neuronal Subtype in Muscle Invasive Bladder Cancer.</i> <i>The Journal of Urology</i> 209 (Supplement 4), e1195, 2023</li>
                  <li><em>Oral Presentation, Breakthrough abstract (LBA03-05)</em>: TA Qureshi, X Chen (Speaker), Y Xie, K Murakami, T Sakatani, M Miyake, … <i>Radiogenomics Of Muscle Invasive Bladder Cancer.</i> <i>The Journal of Urology</i> 209 (Supplement 4), e1193, 2023</li>
                </ul>
              </li>
              <li><strong>American Urological Association (AUA) Annual Meeting 2025 – Las Vegas, NV</strong>:
                <ul>
                  <li>Shen Y, Chen X, Choi S, Knott SRV, Theodorescu D. <i>IP14-09 Y Chromosome Loss Promotes Neuroendocrine Differentiation In Bladder Cancer.</i> <i>The Journal of Urology</i> 213(5S): e750, 2025</li>
                </ul>
              </li>
            </ul>
          </div>
        </section>

        <!-- CONTACT -->
        <section id="contact">
          <div class="container">
            <header class="major"><h2>Contact</h2></header>
            <p>Email: <a href="mailto:xchen295@jh.edu">xchen295@jh.edu</a></p>
            <p>Location: Baltimore, MD</p>
            <p>Download my current CV: <a href="https://cheery-sorbet-5f1409.netlify.app/docs/Xingyu_Chen_CV.pdf" target="_blank">PDF Version</a></p>
            <ul class="icons">
              <li><a href="https://x.com/Xingyu_Chen_" class="icon brands fa-twitter" target="_blank"><span class="label">Twitter</span></a></li>
              <li><a href="https://scholar.google.com/citations?user=Vj8vClIAAAAJ&hl=en&oi=ao" class="icon solid fa-graduation-cap" target="_blank"><span class="label">Google Scholar</span></a></li>
              <li><a href="https://orcid.org/0000-0002-9284-4950" target="_blank"><img src="images/orcid.png" alt="ORCID" class="orcid-icon"/></a></li>
            </ul>
          </div>
        </section>
      </div>
    </div><!-- /wrapper -->

    <!-- FOOTER -->
    <section id="footer">
      <div class="container">
        <ul>
          <li>&copy; 2025 Xingyu Chen</li>
          <li>Design: Read Only by ajlkn via <a href="https://html5up.net" target="_blank">HTML5 UP</a></li>
        </ul>
      </div>
    </section>

    <!-- scripts -->
    <script src="assets/js/jquery.min.js"></script>
    <script src="assets/js/jquery.scrollex.min.js"></script>
    <script src="assets/js/jquery.scrolly.min.js"></script>
    <script src="assets/js/browser.min.js"></script>
    <script src="assets/js/breakpoints.min.js"></script>
    <script src="assets/js/util.js"></script>
    <script src="assets/js/main.js"></script>
    <script>document.getElementById("mlink").href="mailto:xchen295@jh.edu";</script>
    <script src="https://badge.dimensions.ai/badge.js" charset="utf-8"></script>
    <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script>
  </body>
</html>
